HIGHLIGHTS
- who: Mingye Zhao and collaborators from the School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China have published the paper: Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis, in the Journal: (JOURNAL)
- what: The aim of this study is to compare the cost-effectiveness of nemonoxacin and levofloxacin in the treatment of CAP and to determine the value of these treatments in the differential diagnosis of PTB. The effect index used during this study was the quality-adjusted life day (QALD), and the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.